13 мая 2024 г. · “SELECT was a well conducted randomised controlled trial which looked at the effects of semaglutide on cardiovascular disease events in people ...

13 мая 2024 г. · In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with ...

24 авг. 2024 г. · We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes.

Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes.

12 сент. 2024 г. · Once-weekly subcutaneous semaglutide was associated with a decreased risk of MACE comprised of CV death, nonfatal MI, and stroke compared with placebo.

19 дек. 2023 г. · They are also known to be associated with reduced cardiovascular mortality in patients with type 2 diabetes, however cardiovascular benefit of ...

8 авг. 2023 г. · The results of the SELECT trial show that effective and long term support with losing weight with Wegovy, the results of which are unattainable ...

30 авг. 2024 г. · Compared to placebo, patients treated with semaglutide 2.4 mg had lower rates of all-cause death, driven similarly by CV and non-CV death.

24 авг. 2024 г. · In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure ...

13 нояб. 2023 г. · It's evident therefore that the data from the SELECT trial are not generalizable. Clearly more research is required to resolve the question of ...